Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00526656 · ClinicalTrials.gov registry record · Phase 2
Sunitinib in Treating Patients With Locally Advanced Bladder Cancer
A Phase 2 study, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT00526656 is a Phase 2 study that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 9 participants.
The verdict
NCT00526656, a Phase 2 study, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving sunitinib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This phase II trial is studying the side effects and how well sunitinib works in treating patients with locally advanced bladder cancer.
Interventions
- DRUG sunitinib malate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2007-09 |
| Est. Completion | 2011-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00526656
The ClinicalTrials.gov registry entry for NCT00526656 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which sunitinib malate is the first listed.
NCT00526656 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00526656 about?
NCT00526656 is a clinical study titled "Sunitinib in Treating Patients With Locally Advanced Bladder Cancer". RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving sunitinib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This phase II ...
What is the current status of trial NCT00526656?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2007-09. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00526656?
The interventions under investigation include: sunitinib malate (DRUG).
Who is sponsoring clinical trial NCT00526656?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.